Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

Launched by XIJING HOSPITAL OF DIGESTIVE DISEASES · Dec 12, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at different treatments to see which one works best for getting rid of a bacteria called Helicobacter pylori (H. pylori) in adults aged 18 to 70. H. pylori can cause stomach issues like ulcers and gastritis, so the trial aims to compare two types of treatments: one is a combination of medications that includes vonoprazan, and the other is a combination that includes rabeprazole and bismuth. Researchers want to find out how effective these treatments are in clearing the infection, as well as how well patients feel after treatment and any side effects they might experience.

To participate in this trial, individuals should be between 18 and 70 years old and must have a confirmed H. pylori infection along with related stomach problems. Women who can become pregnant will need to use contraception during the study. Participants can expect to receive treatment and will be monitored for any side effects and how well they respond to the treatment over a few weeks. It's important to know that anyone with certain health issues, recent treatments, or allergies to the study medications will not be eligible to join the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-70 years, regardless of sex; chronic gastritis, peptic ulcer or dyspeptic symptoms, clear Hp infection (positive 13C-urea breath test); voluntary Hp eradication treatment; women of childbearing age are required to use a medically desirable form of contraception during the trial and for 1 month after the trial.
• Exclusion Criteria:
• • Have contraindications to the study drug or are allergic to the study drug; have taken a PPI within 2 weeks and an antibiotic or bismuth within 4 weeks; pregnant and lactating women; and Have undergone upper gastrointestinal surgery; refluse to sign the informed consent document.